Stay updated on STR1VE Gene Replacement Therapy Clinical Trial

Sign up to get notified when there's something new on the STR1VE Gene Replacement Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the STR1VE Gene Replacement Therapy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:30:38.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the gene replacement therapy clinical trial for participants with Spinal Muscular Atrophy Type 1, focusing on the Phase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi.
    Difference
    0.1%
    Check dated 2024-06-06T14:26:39.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants with SMA Type 1, specifying genetic and health conditions required for inclusion. Previously, no information was provided about the participation criteria for collaborators and investigators.
    Difference
    40%
    Check dated 2024-05-22T21:25:04.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T23:12:44.000Z thumbnail image

Stay in the know with updates to STR1VE Gene Replacement Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the STR1VE Gene Replacement Therapy Clinical Trial page.